Tonix soars as CEO presents at conference

CEO Seth Lederman makes the case for Tonix Pharmaceuticals (TNXP +29.1%) at the LD Micro VI conference in Los Angeles, though his presentation doesn't appear to contain any new information.

Webcast and presentation slides

Results from the pivotal Phase 2b/3 trial of TNX-102 SL for fibromyalgia are expected in 2014 H2, and the Phase 2a trial of the drug for treating PTSD is expected to begin in 2014 Q2.

Earlier this week: SA Pro's Joe Springer on the opportunity in Tonix.

Comments (7)
  • buyandhold???
    , contributor
    Comments (907) | Send Message
    this is just the start, its a steal at today's prices....$30 within 12 months before the test results leaves it a $120M market cap
    4 Dec 2013, 05:42 PM Reply Like
  • toosmarttofail
    , contributor
    Comments (699) | Send Message
    Chart looks good, but a lot of people got in at 2, and now you're passing seven. Retracement will occur at some piont, and that can be nasty when you're dealing with biotech swing traders.


    You're at almost triple the low and less than half the high. Upside exists but not like it did a month ago.


    The time to jump on stocks like this is when everyone is jumping off.
    5 Dec 2013, 12:28 AM Reply Like
  • sheldond
    , contributor
    Comments (1449) | Send Message
    There is nothing quite as fun as the technical trader speaking based only on charts.


    Also your discussion of price is funny because it doesn't even mention value. Once you figure that out well its too late.


    6 Dec 2013, 07:02 PM Reply Like
  • toosmarttofail
    , contributor
    Comments (699) | Send Message
    I said "chart looks good." That is because even with the big gains, this stock is blowing through normal trading resistance. That indicates it's a "new stock."


    You could have had this stock for $5 on the same news that now costs $9. People who got in at $5 can take almost double their money at any time.


    My preference is for stocks that are just turning the corner rather than those which have already eaten up 75 percent of any profits going forward.


    Did you get in at $2.25?
    7 Dec 2013, 02:52 PM Reply Like
  • toosmarttofail
    , contributor
    Comments (699) | Send Message
    Where is the value in getting in at double the price on the same news?


    Charts work for a reason: traders have habits. ONe such habit is three-steps-forward/tw... when a stock makes a bull run, so they can buy on the dips and increase their trading profits. Long-term investors are sloppy about the short term and easily scalped by day-tradres who can take 1-2 percent or even 5-10 percent in the short run.


    When I see a stock running up insanely, and media articles telling me to buy it, my instincts say to tread with caution. Every company has a story. When a company has a market cap of $50m, it's very easy for a fat finger to manipulate the price.


    Now if you want to be Warrren Buffet, with tthis stock, just keep buiying and know one day you'll be proven right. For me the stock to do that with is ACTC. I don't care about technical analysis because ACTC has a cure for blindness, and lots of other tsuff, so the dips just give people more time to get in.


    Is Tonix that promising? Maybe. If they are, keep loading up becuase at this market cap it's a steal.
    7 Dec 2013, 03:02 PM Reply Like
  • toosmarttofail
    , contributor
    Comments (699) | Send Message
    Still holding at $9.03. Could go far either way. More interested in stocks that just got crushed or which appear to have turned the corner but not which have quadrupled since the low.
    10 Dec 2013, 04:45 PM Reply Like
  • superflysanta
    , contributor
    Comment (1) | Send Message
    thinking you can do better than a very solid company with a real good chance of success with their drugs sitting well below a fair valuation is some hubris indeed. a fitting internet moniker.
    11 Dec 2013, 09:13 AM Reply Like
DJIA (DIA) S&P 500 (SPY)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs